Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Backed by Semaglutide launches, the company reported 47% quarter-on-quarter revenue growth in Q4 FY26, with EBITDA expanding more than fivefold
Nearly one in five women worldwide are now living with obesity
In the new study, scientists at the University of Virginia used gene-editing techniques to modify GLP-1 receptors in mice to make them more humanlike
The standout story remains Wegovy, particularly its new oral formulation
The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
OneSource is the contract development and manufacturing organization (CDMO) partner for this product
Hyderabad-based peptide specialist strengthens complex generics credentials as Apotex prepares for U.S. commercialization of semaglutide injection
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
